Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental cancer drugs
EPI-7386
Другие языки:

    EPI-7386

    Подписчиков: 0, рейтинг: 0
    EPI-7386
    Clinical data
    Routes of
    administration    		 By mouth
    Drug class N-Terminal domain antiandrogen

    EPI-7386 is an N-terminal domain antiandrogen, or antagonist of the N-terminal domain (NTD) of the androgen receptor (AR), which is under development for the treatment of prostate cancer. The compound was developed as a successor of previous drugs in the EPI series such as EPI-001, ralaniten (EPI-002), and ralaniten acetate (EPI-506). EPI-7386 shows 20-fold higher antiandrogenic potency than ralaniten in vitro (IC50 = 535 nM vs. 9,580 nM, respectively), as well as greater stability in human hepatocytes. It is planned to enter phase I clinical trials in 2020.



    Новое сообщение